PULSE BIOSCIENCES INC (PLSE)
Health Care · Cardiac ablation devices / electrophysiology · NASDAQ
Pulse Biosciences is a medical device company developing proprietary nanosecond pulsed-field ablation technology to treat atrial fibrillation and other surgical soft tissue conditions with nonthermal cellular precision.
What PULSE BIOSCIENCES INC does
Pulse Biosciences develops and commercializes Nanosecond Pulsed-Field Ablation (nsPFA) technology, a proprietary energy modality that delivers nanosecond-duration electrical pulses to nonthermally ablate targeted cells without thermal damage. The company's nPulse System platform is used to treat benign skin lesions, soft tissue ablation in surgical settings, and is being developed for atrial fibrillation treatment in both percutaneous and surgical approaches. The company is refocusing its primary efforts on cardiac electrophysiology applications for atrial fibrillation treatment, which represents a multi-billion-dollar market opportunity.
Themes: ["Atrial fibrillation ablation / cardiac electrophysiology","Nonthermal tissue ablation","Surgical soft tissue ablation","Percutaneous medical devices","Benign thyroid nodule treatment"]
Fundamentals
- Price$27.24 as of 2026-07-09 close
- Market cap$1.9B as of 2026-07-10
- 1-year return+68.3% as of 2026-07-09 close
- Net margin-7376.7% as of 2026-07-10
- Gross margin-21.0% as of 2026-07-10
- ROE-86.7% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Revenue growth (YoY)-20.6% as of 2026-07-10
- Revenue CAGR (3y)-20.6% SEC XBRL
- Beta1.59 as of 2026-07-10
Key risks (from latest filing)
["Company is unprofitable with negative net margin of -7376.7% and declining revenue (-20.63% YoY), indicating significant cash burn and commercialization challenges","Dependence on successful completion of cardiac clinical trials (PRECISE BTN thyroid study, cardiac catheter feasibility studies) and FDA regulatory clearances for new indications, with uncertain timelines and outcomes","Competition from established ablation technologies and cardiac device manufacturers in the atrial fibrillation treatment market, with limited current commercial traction beyond pilot programs and early evaluations"]
Competitors & peers
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.